m7583
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 31, 2016 (NCT02825836)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tyrosine-protein kinase BTKINHIBITOR
BTK inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- m7583
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03297983 | Phase 1 | Oct 9, 2017 | Merck KGaA |
| NCT02825836 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2016 | Merck KGaA, Merck Serono |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck KGaA | For profit | 2 | 1 | 2 | 2016 |
| Merck Serono | For profit | 1 | 1 | 1 | 2016 |
2 organizations
Page 1 / 1